All In Biotech

NDA 216951 · Glaxosmithkline

Jesduvroq

Daprodustat · Oral · Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor

NovelDiscontinued

CDER novel approval, Feb 1, 2023: To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months

Last checked: Nov 19, 2026Latest source record: Feb 1, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Feb 1, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

38

10 Phase 3, 0 recruiting

FAERS reports

1,993

1,889 serious, 439 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS JESDUVROQ increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE) [see Warnings and Precautions ( 5.1 )] . Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels [see Warnings and Precautions ( 5.1 )] . No trial has identified a hemoglobin target level, dose of JESDUVROQ, or dosing strategy that does not increase these risks [see Dosage and Administration ( 2.4 )]. Use the lowest dose of JESDUVROQ sufficient to reduce the need for red blood cell transfusions [see Dosage and Administration ( 2.4 )] . WARNING: INCREASED RISK OF DEATH,...

What it is approved for

From the label in effect Aug 30, 2023.

JESDUVROQ is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. Limitations of Use JESDUVROQ has not been shown to improve quality of life, fatigue, or patient well-being. JESDUVROQ is not indicated for use: • As a substitute for red blood cell transfusions in patients who require immediate correction of anemia. • For treatment of anemia of chronic kidney disease in patients who are not on dialysis. JESDUVROQ is a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least four months. ( 1 ) Limitations of Use Not shown to improve quality of life, fatigue, or patient well-being. Not indicated for use: • As a substitute for transfusion in patients requiring immediate correction of anemia. • In patients not on dialysis.

Mechanism: Daprodustat is a reversible inhibitor of HIF-PH1, PH2 and PH3 (IC 50 in the low nM range). This activity results in the stabilization and nuclear accumulation of HIF-1α and HIF-2α transcription factors, leading to increased transcription of the HIF-responsive genes, including erythropoietin.

Therapeutic areas: Hematology and blood cancers · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • JESDUVROQ · DAPRODUSTAT 6MG · TABLET, ORAL · Discontinued
  • JESDUVROQ · DAPRODUSTAT 2MG · TABLET, ORAL · Discontinued
  • JESDUVROQ · DAPRODUSTAT 8MG · TABLET, ORAL · Discontinued
  • JESDUVROQ · DAPRODUSTAT 4MG · TABLET, ORAL · Discontinued
  • JESDUVROQ · DAPRODUSTAT 1MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Daprodustat" as an intervention, any sponsor and status, largest first.

All 38 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hospitalisation299
  • off label use166
  • product use issue160
  • death118
  • haemoglobin decreased102
  • renal impairment97
  • cardiac failure94
  • haemoglobin increased85
  • dysphagia83
  • nephrogenic anaemia73
  • marasmus64
  • cerebral infarction59

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20172
201823
201920
202012
202153
202247
2023550
2024487
2025489
2026310

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Jesduvroq (Daprodustat)

2024 spending

$23K

Beneficiaries

11

38 claims

Per beneficiary

$2,050

$18.17 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$22,551

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 39 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.